A randomized, controlled, open-label, phase 2 study of Cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma

Project: Research

StatusActive
Effective start/end date14/01/2013/01/25

Keywords

  • clinical trial
  • phase 2 study
  • treatment efficacy
  • cell carcinoma